Working… Menu

Multimode Laser Optoacoustic Ultrasonic Tomography System for Breast Cancer Care - LOUIS-3D Breast Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01755130
Recruitment Status : Unknown
Verified January 2019 by M.D. Anderson Cancer Center.
Recruitment status was:  Active, not recruiting
First Posted : December 24, 2012
Last Update Posted : January 11, 2019
TomoWave Laboratories, Inc.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

Brief Summary:
The goal of this clinical research study is to learn if an imaging device called the Laser Optoacoustic and Ultrasonic Imaging System Assembly (LOUISA-3D) is effective in detecting and monitoring changes in breast tumors.

Condition or disease Intervention/treatment Phase
Breast Cancer Procedure: LOUIS-3D Imaging Procedure Not Applicable

Detailed Description:

If you agree to take part in this study, you will have the LOUISA-3D scan performed within 7 days (+/- 2 days) after you have mammography or ultrasound scans.

If you have a routine biopsy scheduled, the LOUISA-3D scan will be performed within 7 days (+/- 2 days) before that biopsy.

For the LOUISA-3D procedure, you will lay down on a specially-designed breast exam table and you will place your breast in a bowl-like imaging cup. The imaging cup will be filled with a gel that will help send signals to the imaging machine.

The procedure will produce 2 types of images. For the first type, the imaging cup will deliver light from a laser that will travel into your breast and tumor. The light is designed to detect acoustic waves which produce an image. Even though all light will be contained in the imaging cup, you will wear laser safety goggles during the procedure.

For the second type of image, the imaging cup will deliver an ultrasound to your breast which will produce an ultrasound image.

During the scans, the imaging cup will rotate around the breast to create 3-dimensional pictures. The scans may be repeated several times. The entire LOUISA-3D procedure should take about 30 minutes to complete.

Length of Study:

You will be off study after the LOUISA-3D imaging procedure is complete.

This is an investigational study. The LOUISA-3D device is not FDA approved or commercially available. The use of the LOUISA-3D device to detect and monitor changes in breast tumors is investigational.

Up to 96 participants will be enrolled in this study. All will be enrolled at MD Anderson.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 96 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Multimode Laser Optoacoustic Ultrasonic Tomography System for Breast Cancer Care
Actual Study Start Date : May 2014
Estimated Primary Completion Date : May 2020
Estimated Study Completion Date : May 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: LOUIS-3D Imaging Procedure

Part I Years 1-4: Years 1-4 to develop and calibrate the LOUIS-3D machine. The subject of this project is to successfully obtain diagnostic imaging of breast tumors with new imaging technology, laser Optoacoustic Tomography system.

Part 2 Year 5: Goal of part 2 to estimate and compare the false positive rate of LOUIS-3D compared to standard of care ultrasound. Patients will have had a positive standard of care ultrasound requiring a biopsy (gold standard). The LOUIS-3D images will be obtained within 7 days of the standard of care ultrasound.

Procedure: LOUIS-3D Imaging Procedure
LOUIS-3D imaging procedure either on the same day or within 10 days of a regular scheduled visit for a mammogram, ultrasound, magnetic resonance imaging (MRI) scan, or any other breast imaging procedure, between 1 and 7 days before scheduled biopsy. Results of the LOUIS-3D imaging scans compared with results of other imaging scan(s). Entire LOUIS-3D procedure should take about 30 minutes to complete.
Other Name: x-ray

Primary Outcome Measures :
  1. LOUIS 3D Capability to Detect and Differentiate Breast Tumors [ Time Frame: 1 day ]
    The primary aim of this study is to successfully obtain images from LOUIS 3D and assess pathology in order to guide image calibration and gain knowledge about LOUIS 3D capabilities. Pathology will provide useful information including but not limited to type of malignancy, tissue type, and other qualitative information that is necessary for image calibration.

Secondary Outcome Measures :
  1. Comparison of False Positive Rate of LOUIS-3D Compared to Ultrasound for Breast Cancer Detection [ Time Frame: 1 day ]
    Secondary objective is to determine optimal scanning parameters by assessing certain machine parameters (e.g. illumination and detection conditions, laser pulse repetition rate, ultrasound emission characteristics, detection probe, coupling medium characteristics, software and firmware, etc.), anatomical information (speed of sound image, acoustic attenuation image, acoustic scattering image), and functional information (total hemoglobin distribution [THb] / image of angiogenesis density, image of blood oxygen saturation [SO2], and image of water distribution). Continuous variables summarized using descriptive statistics such as mean, standard deviation, median and range. Categorical variables tabulated by frequencies and the corresponding percentages.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Mass palpable or nonpalpable
  2. Tissue density - all tissue types
  3. Menses - any stage of cycle
  4. Age between 20-85 inclusive
  5. Suspicious breast mass(es) defined by mammography or ultrasound indicating biopsy is needed (biopsy not needed if previous biopsy results are available on target lesion(s)).
  6. Tumor location - the mammography or ultrasound report should not say that the tumor is in close proximity of chest wall
  7. Any tumor type (patients with inflammatory breast cancer may be included).

Exclusion Criteria:

  1. Patient is unable or unwilling to give informed consent for any reason
  2. Disability (psychiatric, neurological or physical, which precludes examination)
  3. Patient has tattoos on the region of interest.
  4. Overweight over 250 LB
  5. Very large breast size exceeding 6 inch diameter
  6. Patient has body piercing jewelry through the nipple that cannot be removed.
  7. Patient has had a core or excisional biopsy in the ipsilateral breast within the last 2 weeks (patients with previous fine needle aspirations but no ultrasound evidence of hematoma or post bx change may be included).
  8. Patient has inflammatory skin disease (i.e., psoriasis, eczema) or other irritation affecting the breast.
  9. Patient has any pain or high sensitivity in the breast
  10. Currently taking hormonal replacement therapy
  11. Non-ambulatory or unable to comply with exam
  12. Pregnant (pregnancy test is not required, only as confirmed by patient).
  13. Breastfeeding
  14. Prior breast treatment for target lesion
  15. Previous surgery of the breast in the last 3 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01755130

Layout table for location information
United States, Texas
University of Texas MD Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
TomoWave Laboratories, Inc.
Layout table for investigator information
Principal Investigator: Wei Yang, MD M.D. Anderson Cancer Center
Additional Information:
Layout table for additonal information
Responsible Party: M.D. Anderson Cancer Center Identifier: NCT01755130    
Other Study ID Numbers: 2012-0210
NCI-2014-01243 ( Registry Identifier: NCI CTRP )
First Posted: December 24, 2012    Key Record Dates
Last Update Posted: January 11, 2019
Last Verified: January 2019
Keywords provided by M.D. Anderson Cancer Center:
Breast Cancer
Breast Study
Multimode Laser Optoacoustic Ultrasonic Tomography System
Mass palpable or nonpalpable
Breast lesions
Ductal carcinomas
Lobular carcinomas
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases